Therefore, the incomplete blocking of checkpoint signaling due to the high prevalence of PD‐L2 expression in HNSCC might be one of the reasons for the lower toxicity of PD‐L1 inhibitors. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.